Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens.

Glaser AK, Reder NP, Chen Y, McCarty EF, Yin C, Wei L, Wang Y, True LD, Liu JTC.

Nat Biomed Eng. 2017 Jul;1(7). pii: 0084. doi: 10.1038/s41551-017-0084. Epub 2017 Jun 26.

2.

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD.

Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19.

3.

Utility of Pathology Imagebase for standardisation of prostate cancer grading.

Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hörnblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M.

Histopathology. 2018 Jul;73(1):8-18. doi: 10.1111/his.13471. Epub 2018 Mar 5.

PMID:
29359484
4.

Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review.

Graham L, True LD, Schweizer MT.

Clin Genitourin Cancer. 2018 Apr;16(2):e335-e338. doi: 10.1016/j.clgc.2017.09.012. Epub 2017 Oct 3. No abstract available.

PMID:
29066074
5.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

PMID:
29017058
6.

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB.

Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7.

PMID:
28389510
7.

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.

Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3.

8.

MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD.

PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016.

9.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

10.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
11.

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer.

Nghiem B, Zhang X, Lam HM, True LD, Coleman I, Higano CS, Nelson PS, Pritchard CC, Morrissey C.

Asian J Urol. 2016 Oct;3(4):223-228. doi: 10.1016/j.ajur.2016.09.002. Epub 2016 Sep 12.

12.

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Eur Urol Focus. 2016 Jun;2(2):180-188.

13.

Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L.

Prostate. 2016 Nov;76(15):1409-19. doi: 10.1002/pros.23225. Epub 2016 Jun 21.

14.

Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling.

Lawless ME, Tretiakova MS, True LD, Vakar-Lopez F.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):180-185. doi: 10.1097/PAI.0000000000000401.

PMID:
27299187
15.

Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression.

Zrazhevskiy P, Akilesh S, Tai W, Queitsch K, True LD, Fromm J, Wu D, Nelson P, Stamatoyannopoulos JA, Gao X.

Angew Chem Int Ed Engl. 2016 Jul 25;55(31):8975-8. doi: 10.1002/anie.201603945. Epub 2016 Jun 7.

16.

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA.

Mod Pathol. 2016 Aug;29(8):904-14. doi: 10.1038/modpathol.2016.88. Epub 2016 May 13.

17.

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.

18.

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.

Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.

19.

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS.

Nat Med. 2016 Apr;22(4):369-78. doi: 10.1038/nm.4053. Epub 2016 Feb 29.

20.

Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2.

Ho ME, Quek SI, True LD, Seiler R, Fleischmann A, Bagryanova L, Kim SR, Chia D, Goodglick L, Shimizu Y, Rosser CJ, Gao Y, Liu AY.

Oncotarget. 2016 Mar 29;7(13):15747-56. doi: 10.18632/oncotarget.7400.

21.

Tissue-of-origin-specific gene repositioning in breast and prostate cancer.

Meaburn KJ, Agunloye O, Devine M, Leshner M, Roloff GW, True LD, Misteli T.

Histochem Cell Biol. 2016 Apr;145(4):433-46. doi: 10.1007/s00418-015-1401-8. Epub 2016 Jan 20.

22.

Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, Coleman R, Montgomery B, Lange PH, Roudier M, Higano CS, Bielas JH, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2016 Mar;33(3):239-48. doi: 10.1007/s10585-015-9773-7. Epub 2015 Dec 14.

23.

Locus-specific gene repositioning in prostate cancer.

Leshner M, Devine M, Roloff GW, True LD, Misteli T, Meaburn KJ.

Mol Biol Cell. 2016 Jan 15;27(2):236-46. doi: 10.1091/mbc.E15-05-0280. Epub 2015 Nov 12.

24.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

25.

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.

Macleod LC, Tykodi SS, Holt SK, Wright JL, Lin DW, Tretiakova MS, True LD, Gore JL.

Urology. 2015 Aug;86(2):262-8. doi: 10.1016/j.urology.2015.05.008. Epub 2015 Jul 18.

PMID:
26199164
26.

Integrative Clinical Genomics of Advanced Prostate Cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053. Epub 2015 Jul 16. No abstract available.

27.

Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK.

PLoS One. 2015 Jul 14;10(7):e0132343. doi: 10.1371/journal.pone.0132343. eCollection 2015.

28.

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C.

Clin Cancer Res. 2015 Oct 15;21(20):4698-708. doi: 10.1158/1078-0432.CCR-15-0157. Epub 2015 Jun 12.

29.

ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.

Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrissey C, True LD, Nelson PS, Vasioukhin V.

Cancer Cell. 2015 Jun 8;27(6):797-808. doi: 10.1016/j.ccell.2015.05.005.

30.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

31.

Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.

Arnold RS, Fedewa SA, Goodman M, Osunkoya AO, Kissick HT, Morrissey C, True LD, Petros JA.

Bone. 2015 Sep;78:81-6. doi: 10.1016/j.bone.2015.04.046. Epub 2015 May 5.

32.

A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.

Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA.

Prostate. 2015 Aug 1;75(11):1206-15. doi: 10.1002/pros.23003. Epub 2015 May 4.

33.

Sequencing small genomic targets with high efficiency and extreme accuracy.

Schmitt MW, Fox EJ, Prindle MJ, Reid-Bayliss KS, True LD, Radich JP, Loeb LA.

Nat Methods. 2015 May;12(5):423-5. doi: 10.1038/nmeth.3351. Epub 2015 Apr 6.

34.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

35.

More accurate ways to measure tumor cellularity.

True LD.

Am J Clin Pathol. 2014 Dec;142(6):880. doi: 10.1309/AJCPGL9E3HCXFZTP. No abstract available.

PMID:
25389344
36.

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.

37.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

38.

Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG.

Ann Diagn Pathol. 2014 Dec;18(6):333-42. doi: 10.1016/j.anndiagpath.2014.08.010. Epub 2014 Sep 3.

PMID:
25263387
39.

Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS.

PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014.

40.

Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity.

Williamson SR, Cheng L, Eble JN, True LD, Gupta NS, Wang M, Zhang S, Grignon DJ.

Mod Pathol. 2015 Feb;28(2):279-94. doi: 10.1038/modpathol.2014.105. Epub 2014 Sep 5.

41.

Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports.

Mossanen M, True LD, Wright JL, Vakar-Lopez F, Lavallee D, Gore JL.

Hum Pathol. 2014 Nov;45(11):2192-201. doi: 10.1016/j.humpath.2014.07.008. Epub 2014 Jul 25. Review.

PMID:
25149550
42.

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS.

Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13.

43.

Readability of urologic pathology reports: the need for patient-centered approaches.

Mossanen M, Calvert JK, Wright JL, True LD, Lin DW, Gore JL.

Urol Oncol. 2014 Nov;32(8):1091-4. doi: 10.1016/j.urolonc.2014.04.011. Epub 2014 May 17. Review.

PMID:
24846343
44.

Prognostic biomarkers: an introduction.

Bosman FT, True LD.

Virchows Arch. 2014 Mar;464(3):253-6. doi: 10.1007/s00428-014-1553-2. Epub 2014 Feb 22. No abstract available.

PMID:
24562304
45.

Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.

Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL.

Am J Surg Pathol. 2014 Mar;38(3):333-8. doi: 10.1097/PAS.0000000000000162.

46.

Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice.

True LD.

Virchows Arch. 2014 Mar;464(3):257-63. doi: 10.1007/s00428-013-1531-0. Epub 2014 Feb 1. Review.

47.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

48.

Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices.

Lee F, Gottsch H, Ellis WJ, True LD, Lin DW, Wright JL.

Adv Urol. 2013;2013:471234. doi: 10.1155/2013/471234. Epub 2013 Oct 24.

49.

Multicolor multicycle molecular profiling with quantum dots for single-cell analysis.

Zrazhevskiy P, True LD, Gao X.

Nat Protoc. 2013 Oct;8(10):1852-69. doi: 10.1038/nprot.2013.112. Epub 2013 Sep 5.

50.

Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS.

J Pathol. 2013 Jul;230(3):291-7. doi: 10.1002/path.4180.

Supplemental Content

Support Center